The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival

Chih Hsiang Wang, Chia-Ching Wu, Shan Hui Hsu, Jun Yang Liou, Yu Wei Li, Kenneth K. Wu, Yiu Kay Lai, B. Linju Yen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Current advances in stem cell biology have brought much hope for therapy of neuro-degenerative diseases. However, neural stem cells (NSCs) are rare adult stem cells, and the use of non-NSCs requires efficient and high-yielding lineage-specific differentiation prior to transplantation for efficacy. We report on the efficient differentiation of placental-derived multipotent cells (PDMCs) into a neural phenotype with use of Y-27632, a clinically compliant small molecular inhibitor of Rho kinase (ROCK) which is a major mediator of cytoskeleton dynamics. Y-27632 does not induce differentiation of PDMC toward the mesodermal lineages of adipogenesis and osteogenesis, but rather a neural-like morphology, with rapid development of cell extensions and processes within 24 h. Compared with conventional neurogenic differentiation agents, Y-27632 induces a higher percentage of neural-like cells in PDMCs without arresting proliferation or cell cycle dynamics. Y-27632-treated PDMCs express several neural lineage genes at the RNA and protein level, including nestin, MAP2, and GFAP. The effect of the ROCK inhibitor is cell-specific to PDMCs, and is mainly mediated through the ROCK2 isoform and its downstream target, myosin II. Our data suggest that ROCK inhibition and cytoskeletal rearrangement may allow for induction of a neural phenotype in PDMCs without compromising cell survival.

Original languageEnglish
Pages (from-to)3223-3230
Number of pages8
JournalBiomaterials
Volume34
Issue number13
DOIs
Publication statusPublished - 2013 Apr 1

Fingerprint

Stem cells
Placenta
Cell Survival
Phosphotransferases
Cells
Phenotype
Cytology
Neurodegenerative diseases
Myosin Type II
Nestin
rho-Associated Kinases
RNA
Protein Isoforms
Genes
Stem Cells
Proteins
Y 27632
Adipogenesis
Adult Stem Cells
Neural Stem Cells

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Wang, Chih Hsiang ; Wu, Chia-Ching ; Hsu, Shan Hui ; Liou, Jun Yang ; Li, Yu Wei ; Wu, Kenneth K. ; Lai, Yiu Kay ; Yen, B. Linju. / The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival. In: Biomaterials. 2013 ; Vol. 34, No. 13. pp. 3223-3230.
@article{3430831f8bdb473a943ac1af7daebf9f,
title = "The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival",
abstract = "Current advances in stem cell biology have brought much hope for therapy of neuro-degenerative diseases. However, neural stem cells (NSCs) are rare adult stem cells, and the use of non-NSCs requires efficient and high-yielding lineage-specific differentiation prior to transplantation for efficacy. We report on the efficient differentiation of placental-derived multipotent cells (PDMCs) into a neural phenotype with use of Y-27632, a clinically compliant small molecular inhibitor of Rho kinase (ROCK) which is a major mediator of cytoskeleton dynamics. Y-27632 does not induce differentiation of PDMC toward the mesodermal lineages of adipogenesis and osteogenesis, but rather a neural-like morphology, with rapid development of cell extensions and processes within 24 h. Compared with conventional neurogenic differentiation agents, Y-27632 induces a higher percentage of neural-like cells in PDMCs without arresting proliferation or cell cycle dynamics. Y-27632-treated PDMCs express several neural lineage genes at the RNA and protein level, including nestin, MAP2, and GFAP. The effect of the ROCK inhibitor is cell-specific to PDMCs, and is mainly mediated through the ROCK2 isoform and its downstream target, myosin II. Our data suggest that ROCK inhibition and cytoskeletal rearrangement may allow for induction of a neural phenotype in PDMCs without compromising cell survival.",
author = "Wang, {Chih Hsiang} and Chia-Ching Wu and Hsu, {Shan Hui} and Liou, {Jun Yang} and Li, {Yu Wei} and Wu, {Kenneth K.} and Lai, {Yiu Kay} and Yen, {B. Linju}",
year = "2013",
month = "4",
day = "1",
doi = "10.1016/j.biomaterials.2012.12.034",
language = "English",
volume = "34",
pages = "3223--3230",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "13",

}

The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival. / Wang, Chih Hsiang; Wu, Chia-Ching; Hsu, Shan Hui; Liou, Jun Yang; Li, Yu Wei; Wu, Kenneth K.; Lai, Yiu Kay; Yen, B. Linju.

In: Biomaterials, Vol. 34, No. 13, 01.04.2013, p. 3223-3230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The role of RhoA kinase inhibition in human placenta-derived multipotent cells on neural phenotype and cell survival

AU - Wang, Chih Hsiang

AU - Wu, Chia-Ching

AU - Hsu, Shan Hui

AU - Liou, Jun Yang

AU - Li, Yu Wei

AU - Wu, Kenneth K.

AU - Lai, Yiu Kay

AU - Yen, B. Linju

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Current advances in stem cell biology have brought much hope for therapy of neuro-degenerative diseases. However, neural stem cells (NSCs) are rare adult stem cells, and the use of non-NSCs requires efficient and high-yielding lineage-specific differentiation prior to transplantation for efficacy. We report on the efficient differentiation of placental-derived multipotent cells (PDMCs) into a neural phenotype with use of Y-27632, a clinically compliant small molecular inhibitor of Rho kinase (ROCK) which is a major mediator of cytoskeleton dynamics. Y-27632 does not induce differentiation of PDMC toward the mesodermal lineages of adipogenesis and osteogenesis, but rather a neural-like morphology, with rapid development of cell extensions and processes within 24 h. Compared with conventional neurogenic differentiation agents, Y-27632 induces a higher percentage of neural-like cells in PDMCs without arresting proliferation or cell cycle dynamics. Y-27632-treated PDMCs express several neural lineage genes at the RNA and protein level, including nestin, MAP2, and GFAP. The effect of the ROCK inhibitor is cell-specific to PDMCs, and is mainly mediated through the ROCK2 isoform and its downstream target, myosin II. Our data suggest that ROCK inhibition and cytoskeletal rearrangement may allow for induction of a neural phenotype in PDMCs without compromising cell survival.

AB - Current advances in stem cell biology have brought much hope for therapy of neuro-degenerative diseases. However, neural stem cells (NSCs) are rare adult stem cells, and the use of non-NSCs requires efficient and high-yielding lineage-specific differentiation prior to transplantation for efficacy. We report on the efficient differentiation of placental-derived multipotent cells (PDMCs) into a neural phenotype with use of Y-27632, a clinically compliant small molecular inhibitor of Rho kinase (ROCK) which is a major mediator of cytoskeleton dynamics. Y-27632 does not induce differentiation of PDMC toward the mesodermal lineages of adipogenesis and osteogenesis, but rather a neural-like morphology, with rapid development of cell extensions and processes within 24 h. Compared with conventional neurogenic differentiation agents, Y-27632 induces a higher percentage of neural-like cells in PDMCs without arresting proliferation or cell cycle dynamics. Y-27632-treated PDMCs express several neural lineage genes at the RNA and protein level, including nestin, MAP2, and GFAP. The effect of the ROCK inhibitor is cell-specific to PDMCs, and is mainly mediated through the ROCK2 isoform and its downstream target, myosin II. Our data suggest that ROCK inhibition and cytoskeletal rearrangement may allow for induction of a neural phenotype in PDMCs without compromising cell survival.

UR - http://www.scopus.com/inward/record.url?scp=84874275277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874275277&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2012.12.034

DO - 10.1016/j.biomaterials.2012.12.034

M3 - Article

C2 - 23410680

AN - SCOPUS:84874275277

VL - 34

SP - 3223

EP - 3230

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 13

ER -